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TCT Meeting will take place in Miami, 22-26/10/12  
 
HCS Meeting to be held in Athens, 1-3/11/12  
 
AHA 2012 is scheduled for Los Angeles, 3-7/11/12 
 
EuroEcho will take place in Athens, 5-8/12/2012 
 
HCS Working Group Seminars: Thessaloniki, 14-16/2/2013  
 
ACC Meeting: San Francisco, 9-11/3/13 
 
HRS Meeting: Denver, 8-11/5/13  
 
EuroPCR: Paris, 21-24/5/13  
 
EuroPace: Athens, 23-26/6/13  
 
ESC Congress: Amsterdam, 31/8-4/9/13  
  
Dennmark Cohort Study: In Patients with AF, 
Interruption of Warfarin Confers Increased Short-
Term Risk of Death or Thrombo-Embolic Events  
In total, 48,989 atrial fibrillation (AF) patients 
receiving warfarin were included in this retrospective 
cohort study. Of these, 35,396 patients had at least one 
episode of warfarin treatment interruption. In all, 8255 
deaths or thromboembolic events occurred during 
treatment interruption showing an initial clustering of 
events during 0–90 days. The first 90-day interval of 
treatment interruption was associated with a markedly 
higher risk of death or thrombo-embolism (incidence rate 
ratio-IRR 2.5) vs the interval of 271–360 days. The 
authors concluded that in this patient population with AF, 
almost 3 out of 4 patients on warfarin treatment had one 
or more periods of treatment interruption. Interruption of 
warfarin therapy was associated with a significantly 
increased short-term risk of thrombo-embolism or death 
during the first 90 days of interruption (Raunso J et al, 
Eur Heart J 2012; 33: 1886–1892).  
 
Left Ventricular Dyssynchrony May Determine 
Outcome Following CRT in Patients with RBBB and 
Help in the Selection of CRT Candidates  
Echocardiography was performed in 561 cardiac 
resynchronization therapy (CRT) recipients (89 with 
RBBB & 472 with LBBB) before and 6 months after 
CRT. RBBB patients had a higher prevalence of male 
gender, ischemic heart disease, atrial fibrillation, and 
lower exercise capacity when compared with LBBB 
patients, despite smaller left ventricular (LV) volumes. In 
addition, the extent of both interventricular and LV 
dyssynchrony was less in RBBB patients. At 6 months, 
RBBB patients also showed limited LV reverse 
remodelling. LV dyssynchrony and mitral regurgitation 
were identified as independent predictors of all-cause 
mortality or heart failure hospitalization among RBBB 
patients. The authors concluded that RBBB patients 
referred for CRT exhibit interventricular and LV 
dyssynchrony, albeit less than their LBBB counterparts; 
preimplantation LV dyssynchrony may be an important 
determinant of death or heart failure hospitalization 
among CRT recipients with RBBB (Leong DP et al, Eur 
Heart J 2012; 33: 1934–1941).  
 
Danish Cohort Study: Psoriasis is Associated With 
Increased Risk of AF and Ischemic Stroke 
In this cohort study of the entire Danish population 
followed from 1997 to 2006, 36,765 patients with mild 
psoriasis and 2,793 with severe psoriasis were compared 
with the reference population (4,478,926 individuals). In 
patients with mild psoriasis, the adjusted rate ratios (RRs) 
for atrial fibrillation (AF) were 1.50 and 1.16 in patients 
aged <50 & ≥50 years, respectively. Patients with severe 
psoriasis had a higher risk of AF with RRs 2.98 in 
patients aged <50 years & 1.29 in patients aged ≥50 
years. Patients with psoriasis also demonstrated a disease 
severity-dependent increased risk of ischemic stroke. The 
authors concluded that psoriasis is a risk factor for AF 
and ischemic stroke with highest risk in young patients 
with severe psoriasis. The results add to accumulating 
evidence indicating that patients with psoriasis are at 
increased cardiovascular risk (Ahlenhoff O et al, Eur 
Heart J 2012; 33, 2054–2064).   
 
CRUSADE Registry: In-hospital Major Bleeding 
Confers Increased Mortality in Older Patients 
Hospitalized for NSTEMI 
Among 32,895 NSTEMI patients aged ≥65 years, 
11.9% (n=3902) had an in-hospital major bleeding event. 
Cumulative mortality was higher in those who had a 
major bleed vs those without at 30 days, 1 year, and 3 
years. Major bleeding was significantly associated with 
higher mortality over time in the overall population: (i) 
discharge to 30 days (hazard ratio-HR 1.33); (ii) 31 days-
1 year (1.19); (iii) 1-3 years (1.09), & (iv) attenuating 
beyond 3 years (1.14). In-hospital bleeding continued to 
be significantly associated with higher mortality even 
beyond 3 years (1.25). The authors concluded that in-
hospital major bleeding is associated with short-, 
intermediate-, and long-term mortality among older 
patients hospitalized for NSTEMI—this association is 
strongest within the first 30 days. Regarding the longer 
duration of risk, major bleeding rather identifies patients 
with an underlying risk for mortality (Lopes RD et al, 
Eur Heart J 2012; 33: 2044–2053).  
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LIPSIA-NSTEMI Trial: No Advantage of Immediate 
Invasive Over an Early or a Selective Invasive 
Approach in NSTEMI Patients 
Patients with NSTEMI were randomized to either an 
immediate (<2 h; n=201), an early (10–48 h; n=200), or a 
selective invasive approach (n=201). The median time 
from randomization to angiography was 1.1 h in the 
immediate vs 18.6 h in the early & 67.2 h in the selective 
invasive group (P<0.001). There was no significant 
difference in the peak CK-MB activity among groups. 
The key secondary clinical endpoints were similar among 
groups at 6-month follow-up: death and infarction: 21 vs 
16 vs 14.5%; P=NS; death, infarction, refractory 
ischemia: 20.9 vs. 21.5 vs. 22%; P=NS; death, infarction, 
refractory ischemia, rehospitalization: 26.0 vs. 26.5 vs. 
24.5%; P=NS. The authors concluded that in NSTEMI 
patients, an immediate invasive approach does not offer 
an advantage over an early or a selective invasive 
approach with respect to large myocardial infarctions as 
defined by peak CK-MB levels, which is supported by 
similar clinical outcomes (Thiele H et al, Eur Heart J 
2012;33:2035–2043).  
 
LBBB Induced by TAVI Increases Risk of Death  
Of 679 patients analyzed, 387 (57%) underwent TAVI 
with the Medtronic CoreValve system and 292 (43%) 
with the Edwards SAPIEN valve. A total of 233 patients 
(34.3%) developed new LBBB. Median follow-up was 
~450 days. All-cause mortality was 37.8% (n=88) in 
patients with LBBB and 24% (n=107) in patients without 
LBBB (P=0.002). Independent predictors of all-cause 
mortality were TAVI-induced LBBB (hazard ratio -HR, 
1.54), chronic obstructive lung disease (HR, 1.56), female 
gender (HR, 1.39), left ventricular ejection fraction <50% 
(HR, 1.38), and baseline creatinine (HR, 1.32). LBBB 
was more frequent after implantation of the Medtronic 
CoreValve System than after Edwards SAPIEN 
implantation (51% & 12%, respectively; P<0.001), but 
device type did not influence the mortality risk of TAVI-
induced LBBB. The authors concluded that all-cause 
mortality after TAVI is higher in patients who develop 
LBBB than in patients who do not; TAVI-induced LBBB 
is an independent predictor of mortality (Houthuizen P et 
al, Circulation 2012; 126:720-728).  
 
Subclinical Thyroid Dysfunction: Risk of Heart 
Failure Increases both with Lower and Higher TSH 
Levels, particularly with TSH Levels >10.0 mIU/L and 
<0.10 mIU/L 
A pooled analysis of 25,390 participants in 6 
prospective cohorts in US & Europe revealed subclinical 
hypothyroidism (TSH: 4.5-19.9 mIU/L) in 2068 (8.1%) 
and subclinical hyperthyroidism (<0.45 mIU/L) in 648 
(2.6%) (all with normal free thyroxine levels). Risks of 
heart failure events were increased with both higher and 
lower TSH levels (P <0.01); the hazard ratio was 1.01 for 
TSH of 4.5 to 6.9 mIU/L, 1.65 for TSH of 7.0 to 9.9 
mIU/L, 1.86 for TSH of 10.0 to 19.9 mIU/L (P for trend 
<0.01) and 1.31 for TSH of 0.10-0.44 mIU/L and 1.94 for 
TSH <0.10 mIU/L (P for trend=0.047). Risks remained 
similar after adjustment for cardiovascular risk factors. 
The authors concluded that risks of heart failure events 
are increased with both higher and lower TSH levels, 
particularly for TSH >10 and <0.10 mIU/L (Gencer B et 
al, Circulation 2012;126: 1040-1049).  
 
Multiple (>2) Arterial Grafts Improve Late Survival 
of Patients Undegoing CABG 
Among 8622 Mayo Clinic patients who underwent 
coronary artery bypass graft (CABG) surgery for 
multivessel coronary disease (1993-2009) with LIMA 
plus saphenous veins (LIMA/SV) (n=7435) or multiple 
arterial grafts (MultiArt) (n=1187), operative mortality 
was 0.8% (n=10) in the MultArt and 2.1% (n=154) in the 
LIMA/SV (P=0.005) group; not statistically different in 
multivariate or matched analysis (propensity score 
analysis matched 1153 patients). Late survival was 
greater for MultArt vs LIMA/SV. MultArt subgroups 
with bilateral internal mammary artery/SV (n=589) and 
bilateral internal mammary artery only (n=271) had 
improved 15-year survival and patients with bilateral 
internal mammary artery/radial artery (n=147) and 
LIMA/radial artery (n=169) had greater 10-year survival 
vs LIMA/SV. In multivariate analysis, MultArt grafts 
remained a strong independent predictor of survival 
(hazard ratio, 0.79; P=0.007). The authors concluded that 
late outcome of surgical revascularization is improved 
when at least 2 arterial grafts are used (Locker C et al, 
Circulation 2012;126:1023-1030).  
 
Danish Registries: High Risk of Bleeding is 
Immediately Evident with Triple Therapy after 
MI/PCI in Patients with Atrial Fibrillation 
Among 11,480 patients (mean age 75.6 years, males 
61%) with atrial fibrillation admitted with myocardial 
infarction (MI) or for percutaneous coronary intervention 
(PCI) between 2000 and 2009 and within 1 year, 728 
bleeding events were recorded (6.3%); 79 were fatal 
(0.7%). Within 30 days, rates were 22.6, 20.3, and 14.3 
bleeding events per 100 person-years for triple therapy 
(TT) (warfarin/aspirin/clopidogrel), dual therapy 
(warfarin/antiplatelet), and dual antiplatelet therapy 
(aspirin/clopidogrel), respectively. Both early (within 90 
days) and delayed (90–360 days) bleeding risk with TT 
exposure in relation to dual therapy was increased; hazard 
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ratio-HR 1.47 and 1.36, respectively. No significant 
difference in thromboembolic risk was observed for TT 
vs dual therapy; HR, 1.15. The authors concluded that 
high risk of bleeding is immediately evident with TT after 
MI/PCI in patients with atrial fibrillation. A continually 
elevated risk associated with TT indicates no safe 
therapeutic window, and TT should only be prescribed 
after thorough bleeding risk assessment of patients 
(Lamberts M et al, Circulation 2012;126:1185-1193).   
 
Association of Circulating MicroRNAs and Incident 
MI With MiR-223 and MiR-197 Showing Negative 
Associations and MiR-126 Showing a Positive 
Association With Subsequent MIs 
A total of 19 candidate microRNAs were quantified 
by real-time polymerase chain reactions in 820 
participants. In multivariable analysis, 3 microRNAs 
were consistently and significantly related to incident 
myocardial infarction (MI): miR-126 showed a positive 
association (hazard ratio-HR: 2.69, p = 0.002), whereas 
miR-223 and miR-197 were inversely associated with 
disease risk (HR: 0.47, p = 0.002, and 0.56, p = 0.036). 
To determine their cellular origin, healthy volunteers 
underwent limb ischemia-reperfusion generated by thigh 
cuff inflation, and plasma miRNA changes were 
analyzed; 6 distinct miRNA clusters were identified, of 
which one cluster included all miRNAs associated with 
the risk of future MI, predominantly expressed in 
platelets. The authors concluded that their study showed 
an association of circulating miRNAs, as novel 
biomarkers, and incident MI with miR-223 and miR-197 
indicating negative associations and miR-126 showing a 
positive association with subsequent MIs (Zampetaki A et 
al, J Am Coll Cardiol 2012;60:290–299).  
 
XAMI Trial: Second-Generation Everolimus Eluting 
Stents (EES) Display Fewer Cardiac Events than the 
First-Generation Sirolimus Eluting Stents (SES) in 
Acute Myocardial Infarction (AMI) Patients 
A total of 625 patients with AMI were randomized 
(2:1) to receive EES (n=404) or SES (n=221). The major 
adverse cardiac event (MACE) rate was 4.0% for EES 
and 7.7% for SES; relative risk 0.52. One-year cardiac 
mortality was low at 1.5% for EES vs 2.7% for SES 
(p=NS), and 1-year incidence of definite and/or probable 
stent thrombosis was 1.2% for EES vs 2.7% for SES (p = 
NS). The authors concluded that second-generation EES 
were noninferior to SES, while superiority for MACE 
was suggested. Stent thrombosis rate in EES at 1-year 
was low, but long-term follow-up and larger studies are 
needed to show whether very late stent thrombosis rates 
will also be improved in newer DES (Hofma SH et al, J 
Am Coll Cardiol 2012;60:381–387).  
 
Left Atrial Appendage (LAA) Morphology Correlates 
with Risk of Stroke in Atrial Fibrillation (AF): 
Patients with Chicken Wing LAA Morphology are 
Less Likely to Have an Embolic Event  
Among 932 patients with AF (aged 59+10 years, 79% 
male, 14% with CHADS2 score >2) scheduled for 
catheter ablation, CT (n=499) and MRI (n= 433) scans 
were analyzed. The distribution of different LAA 
morphologies was Cactus (n=278; 30%), Chicken Wing 
(n=451; 48%), Windsock (n=179; 19%), and Cauliflower 
(n= 24; 3%). Of the 932 patients, 78 (8%) had a history of 
ischemic stroke or TIA. The prevalence of pre-procedure 
stroke/TIA in Cactus, Chicken Wing, Windsock, and 
Cauliflower morphologies was 12%, 4%, 10%, and 18%, 
respectively (p=0.003). In a multivariable analysis, 
Chicken Wing morphology was found to be 79% less 
likely to have a stroke/TIA history (odd ratio: 0.21, p = 
0.036). Compared with Chicken Wing, Cactus was 4.08 
times (p = 0.046), Windsock was 4.5 times (p = 0.038), 
and Cauliflower was 8.0 times (p = 0.056) more likely to 
have had a stroke/TIA. The authors concluded that 
patients with Chicken Wing LAA morphology are less 
likely to have an embolic event (Di Biase L et al, J Am 
Coll Cardiol 2012;60:531–538).  
 
CONFIRM Trial: A Revolutionary Focal Approach to 
Atrial Fibrillation Ablation  
A computational approach to map and ablate localized 
sources of atrial fibrillation (AF) (focal impulse and rotor 
modulation-FIRM) was developed and compared to 
conventional ablative technique in 92 patients during 107 
consecutive ablation procedures for paroxysmal or 
persistent (72%) AF. Cases were prospectively treated, in 
a 2-arm 1:2 design, by ablation at sources (FIRM-guided) 
followed by conventional ablation (n=36), or 
conventional ablation alone (n=71). Localized rotors or 
focal impulses were detected in 98 (97%) of 101 cases 
with sustained AF, each exhibiting 2.1 + 1.0 sources. The 
acute endpoint (AF termination or consistent slowing) 
was achieved in 86% of FIRM-guided cases vs 20% of 
FIRM-blinded cases (p < 0.001). FIRM ablation alone at 
the primary source terminated AF in a median 2.5 min. 
Total ablation time did not differ between groups. During 
a median 273 days after a single procedure, FIRM-guided 
cases had higher freedom from AF (82.4% vs. 44.9%; p < 
0.001) after a single procedure than FIRM-blinded cases 
with rigorous, often implanted, electrocardiography 
monitoring. Adverse events did not differ between 
groups. The authors concluded that focal impulse and 
rotor modulation (FIRM) ablation to eliminate local 
sources was able to abruptly terminate or consistently 
slow persistent and paroxysmal AF in the vast majority of 
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cases, and substantially improve long-term AF 
elimination over conventional ablation alone (Narayan 
SM et al, J Am Coll Cardiol 2012;60: 628–36)  
 
Coronary Bypass (CABG) Compared with 
Percutaneous Coronary Revascularization (PCI) is 
Associated with an Increased Risk of Stroke 
A meta-analysis of 19 trials including 10,944 patients 
randomized to CABG vs PCI showed that the 30-day rate 
of stroke was 1.20% after CABG compared with 0.34% 
after PCI (odds ratio-OR: 2.94, p < 0.0001). Similar 
results were observed after a median follow-up of 12.1 
months (1.83% vs. 0.99%, OR: 1.67, p = 0.02). The 
extent of coronary artery disease (single vessel vs 
multivessel vs left main) did not affect the relative 
increase in the risk of stroke observed with CABG 
compared with PCI at either 30 days or midterm follow-
up. Similar results were observed when the outcomes in 
33,980 patients from 27 observational studies were 
analyzed. The authors concluded that coronary 
revascularization by CABG compared with PCI is 
associated with an increased risk of stroke at 30 days and 
at the mid-term follow-up (Palmerini T et al, J Am Coll 
Cardiol 2012;60:798–805).  
 
Renal Artery Denervation Reduces Blood Pressure in 
Patients with Drug-resistant Hypertension and 
Reduces AF Recurrences when Combined with 
Pulmonary Vein Isolation (PVI) 
Patients (n= 27) with a history of symptomatic 
paroxysmal or persistent AF refractory to >2 
antiarrhythmic drugs and drug-resistant hypertension 
(systolic blood pressure >160 mm Hg despite triple drug 
therapy) were randomized to PVI only (n=14) or PVI 
with renal artery denervation (n=13). At 1 year, 
significant reductions in systolic (from 181+7 to 156+5, p 
< 0.001) and diastolic blood pressure (from 97+6 to 87+4, 
p<0.001) were observed in patients treated with PVI with 
renal denervation without significant change in the PVI 
only group. Nine of the 13 patients (69%) treated with 
PVI with renal denervation were AF-free vs 4 (29%) of 
the 14 patients in the PVI-only group (p = 0.033). The 
authors concluded that renal artery denervation reduces 
systolic and diastolic blood pressure in patients with 
drug-resistant hypertension and reduces AF recurrences 
when combined with PVI (Pokushalov E et al, J Am Coll 
Cardiol 2012;60:1163–1170).   
 
Rhythm Control Therapy in Atrial Fibrillation Seems 
to be Superior in the Long-term 
Among 26,130 patients aged >66 years hospitalized 
with a diagnosis of atrial fibrillation (AF) receiving new 
drug prescription, and followed for a mean period of 3.1 
years, there were 13,237 deaths (49.5%). After adjusting 
for covariates, we found that the effect of rhythm vs rate 
control drugs changed over time: after a small increase in 
mortality for patients treated with rhythm control in the 6 
months following treatment initiation (hazard ratio-HR, 
1.07), the mortality was similar between the 2 groups 
until year 4 but decreased steadily in the rhythm control 
group after year 5 (HR, 0.89; and HR, 0.77, after 5 and 8 
years, respectively). The authors concluded that little 
difference was found in mortality within 4 years of 
treatment initiation between patients with AF initiating 
rhythm control therapy vs those initiating rate control 
therapy. However, rhythm control therapy seems to be 
superior in the long-term (Ionescu-Ittu R et al, Arch 
Intern Med 2012; 172:997-1004).  
 
Important Review and Other Articles  
 
ESC Guidelines for the diagnosis & treatment of acute & 
chronic heart failure 2012 (McMurray et al, Eur Heart J 
2012; 33:1787-1847), Contrast-induced kidney injury 
(Seeliger E et al, Eur Heart J 2012; 33: 2007-2015), 
High-senstivity cardiac troponins in acute cardiac care 
(Thygesen K et al, Eur Heart J 2012; 33:2252-2257), AF 
ablation (Tung R et al, Circulation 2012; 126:223-229), 
Dietary sodium intake in heart failure (Gupta D et al, 
Circulation 2012; 126;479-485), Periprocedural bridging 
management of anticoagulation (Wysokinski & McBane 
II, Circulation 2012; 126: 486-490), Assessment of 
endothelial function (Flammer AJ et al, Circulation 2012; 
126:753-767), 2012 ACCF/AHA Focused Update of the 
Guideline for the management of patients with unstable 
angina/NSTEMI (Jneid H et al, Circulation 2012; 
126:875-910), Pulmonary hypertension due to left heart 
disease (Guazzi & Borlaug, Circulation 2012; 126: 975-
990), Advances in resuscitation (Mottram & Page, 
Circulation 2012; 126: 991-1002), Acute aortic 
regurgitation (Hamirani YS et al, Circulation 2012; 
126:1121-1126), Body fat distribution and cardiovascular 
risk (Despres J, Circulation 2012; 126:1301-1313), Sleep 
apnea and cardiovascular disease (Kasai T et al, 
Circulation 2012; 126: 1495-1510), Guided 
antithrombotic therapy (Fuster V et al, Circulation 
2012;126: 1645-1662), Current status of TAVI (Webb & 
Wood, J Am Coll Cardiol 2012; 60:483-492), Genetics of 
hypertrophic cardiomyopathy (Maron BJ et al, J Am Coll 
Cardiol 2012; 60: 705-715), Silent brain injury after 
cardiac surgery (Sun X et al, J Am Coll Cardiol 2012; 60: 
791-797), Controversies of statin therapy (Jukema JW et 
al, J Am Coll Cardiol 2012; 60:875-881), Cardiorenal 
syndrome type 1 (Ronco C et al, J Am Coll Cardiol 2012; 
60: 1031-1042).  
